Roche Deals With Huge Gantenerumab Curiosity At H1 Update
Anti-Amyloid Beta Therapy Is In Phase III For Alzheimer's
Roche unveiled a strong Q2 performance driven by new medicines and continued strong growth from its diagnostics division but analysts were most keen for clues on plans for gantenerumab, now in Phase III studies for Alzheimer’s disease.
